Innovative Practice in Breast Health最新文献

{"title":"Artificial intelligence for hierarchical tumor masking potential classification in mammograms","authors":"João Mendes ,&nbsp;Nuno C. Garcia ,&nbsp;Nuno Matela","doi":"10.1016/j.ibreh.2024.100014","DOIUrl":"10.1016/j.ibreh.2024.100014","url":null,"abstract":"<div><p>The most commonly detected cancer type worldwide in 2020 was Breast Cancer (BC). Early diagnosis of this disease, aimed through generalized screening programs with mammography, is imperative to improve BC prognosis. Despite its positive impacts, these programs present some pitfalls. The two-dimensional nature of screening mammography often results in tissue overlap, which can obscure the presence of tumors. This phenomenon contributes to false negative results, potentially delaying cancer diagnosis and compromising disease prognosis. This work proposes an Artificial Intelligence (AI) model capable of analyzing current healthy mammograms and predicting their masking potential. This refers to the likelihood of a potential future cancer, if present, being obscured in subsequent screening mammograms. Given that, 3,000 synthetic mammograms, evenly divided into three masking potential classes Low, Medium, and High were used to train a Convolutional Neural Network (CNN). The performance of the CNN was evaluated using a test set comprising 1,000 mammograms from each masking potential class. Besides that, an independent test set comprised of real instead of synthetic mammograms (<em>N</em> = 201) was also used to assess performance. The F1-score, Specificity, and Accuracy values were very high on the synthetic test set, measuring at 0.976, 0.988, and 0.976, respectively, underscor ing the excellent predictive capability of the CNN. Moreover, the results on the independent test set also show a high classification capacity on the Low and High masking classes in terms of Precision and Specificity. A model like the one proposed here can have significant impacts in the future, allowing personal ized screening based on masking risk, potentially reducing the number of false negative results and ultimately improving the outcomes of this disease.</p></div>","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"3 ","pages":"Article 100014"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950212824000149/pdfft?md5=888159d16a33bcf265f9cfbd0275e395&pid=1-s2.0-S2950212824000149-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142173640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic review of added immunotherapy in traditional treatment for HER2 positive breast cancer patients","authors":"Rohan Choudhari","doi":"10.1016/j.ibreh.2024.100013","DOIUrl":"10.1016/j.ibreh.2024.100013","url":null,"abstract":"<div><h3>Background</h3><p>Breast Cancer is one of the most prevalent cancers in the UK with a variety of subtypes. One of the more invasive and aggressive subtypes is known as ‘HER 2 positive’, referring to the overexpression of HER 2 receptors on cancer cells. Traditionally, surgical intervention alongside chemotherapy in these invasive subtypes is the preferred and recognised treatment. However, recent literature suggests newer immunotherapeutic agents approved by NICE could be beneficial to treat HER 2 Positive patients as an addition or even a substitute over traditional treatments.</p></div><div><h3>Objective</h3><p>To perform a systematic review of added Immunotherapy in traditional treatment in HER2 Positive Breast Cancer Patients</p></div><div><h3>Methods</h3><p>A literature search was conducted using four medical databases in 2022. These were PubMed, Scopus, EMBASE, and Web of Science. The inclusion criteria included Females aged 18 years and above diagnosed with HER2+ breast cancer using immunotherapy as the intervention comparing it with chemotherapy and looking at pCR and survival rates as the outcome. Exclusion criteria was also present excluding terms like ‘triple negative breast cancer’. The Joanna Briggs Institute (JBI) Checklists were used to assess the risk of bias of studies.</p></div><div><h3>Results</h3><p>After study selection processes, seven studies were used in this review. Five of the studies were randomised controlled trials and two of the studies were follow up studies. The randomised controlled trial results clearly showed a better pCR and survival rate for patients which had two immunotherapeutic agents compared to one, and patients who has chemotherapy alongside immunotherapy, compared to patients who only had immunotherapy.</p></div><div><h3>Discussion</h3><p>It was clear that two immunotherapeutic agents alongside chemotherapy was the most effective treatment for patients also producing the best pCR and survival rates. Limitations of studies included short follow up periods and lack of binding of participants in the trials.</p></div>","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"3 ","pages":"Article 100013"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950212824000137/pdfft?md5=9a619717b77d3b3386df710e4d23607e&pid=1-s2.0-S2950212824000137-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142173641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ours","authors":"","doi":"10.1016/S2950-2128(24)00021-6","DOIUrl":"10.1016/S2950-2128(24)00021-6","url":null,"abstract":"","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"3 ","pages":"Article 100021"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142743195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is immediate breast reconstruction surgery safe for elderly women? Assessment of postoperative complications in women aged 70 years and older","authors":"Carlo Arellano ,&nbsp;Caroline Bouche ,&nbsp;Ariane Weyl ,&nbsp;Mony Ung ,&nbsp;Eva Jouve ,&nbsp;Gabrielle Selmes ,&nbsp;Marc Soule-Tholy ,&nbsp;Thomas Meresse ,&nbsp;Carole Massabeau ,&nbsp;Ana Cavillon ,&nbsp;Charlotte Vaysse","doi":"10.1016/j.ibreh.2024.100005","DOIUrl":"10.1016/j.ibreh.2024.100005","url":null,"abstract":"<div><h3>Introduction</h3><p>The rate of immediate breast reconstruction (IBR) in elderly women (EW) is lower than in younger patients because of concerns related to postoperative complications (POC) and their consequences.</p></div><div><h3>Objective</h3><p>We assessed POC 30 days after IBR, readmissions rate within 30 days, and the time to start adjuvant therapy in EW aged ≥ 70 years.</p></div><div><h3>Materials and Methods</h3><p>We conducted an observational, retrospective, single-center study between January 2014 and May 2022 at the University Cancer Institute of Toulouse-Oncopole (IUCT-O), including patients over 70 years old treated with mastectomy and IBR. Patients’ characteristics, medical treatments with the time between therapies and POC were recorded.</p></div><div><h3>Results</h3><p>A total of 125 women aged 70 to 84 years old were included in our study. The rate of IBR was 13.7 %. The rate of major POC was 17.6 % (<em>n</em> = 22), including 9.8 % (<em>n</em> = 11) implant removal. There was significantly more skin necrosis in patients with a history of homolateral radiotherapy (<em>p</em> = 0.016) but less hematoma (<em>p</em> = 0.004). Overweight or obese EW tending to have more than one surgical POC (<em>p</em> = 0.019). EW with nipple-areola complex (NAC) conservation had significantly more skin necrosis (<em>p</em> = 0.01). The median time for initiation of adjuvant chemotherapy (ACT) and hormonal therapy was 5.7 [1.6–11.9] and 4.3 [1.6–78.9] weeks respectively. The median time to initiate adjuvant radiotherapy (ART) when preceded by ACT or not, was 9.2 [5.1–22] and 21.1 [16.9–21.4] weeks respectively.</p></div><div><h3>Conclusion</h3><p>Our study confirms that IBR in women aged ≥ 70 years is safe and does not delay adjuvant therapies.</p></div>","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"2 ","pages":"Article 100005"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950212824000058/pdfft?md5=af050a47b3edea7ab03c602ec38142d9&pid=1-s2.0-S2950212824000058-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141699245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A prospective study to assess the quality of life (QOL) in breast cancer patients and factors affecting quality of life","authors":"Rakesh Kapoor ,&nbsp;Treshita Dey ,&nbsp;Divya Khosla ,&nbsp;Ishita Laroiya","doi":"10.1016/j.ibreh.2024.100004","DOIUrl":"10.1016/j.ibreh.2024.100004","url":null,"abstract":"<div><h3>Introduction</h3><p>Breast cancer is the most prevalent malignancy among women globally, with an incidence rate of 11.7 %, surpassing lung cancer as the most frequently diagnosed cancer. In India, incidence rates begin to increase in the early thirties, peaking between the ages of 50 and 64. Historically, the female population has harbored significant fear towards this particular cancer due to the social stigma associated with the diagnosis. It not only poses a challenge to their self-image but also affects their sexual function, consequently having a negative impact on their psychological well-being. Recent advancements in treatment delivery techniques have decreased breast cancer mortality and enhanced disease-free survival rates. However, ensuring a good quality of life (QOL) remains a challenge. This study was conducted to assess the QOL of breast cancer patients and the factors influencing it.</p></div><div><h3>Materials</h3><p>Patients with histopathological proven malignancy of breast carcinoma aged above 18 years who were registered in our radiotherapy department were included in this cross-sectional study. Patient related, disease related and treatment related parameters were noted. QOL survey instruments used were EORTC-QLQ-C30 version 3.0, EORTC-QLQ-BR23.</p></div><div><h3>Results</h3><p>A total of 160 patients registered in our department from November 2019 to November 2022 were included in this study. The young breast (&lt;45 years) cancer patients showed comparable QOL scores with older patients on most symptomatic and functional scales. The patients with an advanced disease had lowest scores on all functional scales but was not statistically significant. Breast conserving surgery (BCS) correlated very well with better functioning scores in our study though it did not achieve statistical significance. Patients undergoing BCS seemed more confident about their future prospectives and had better sexual enjoyment score. People living in urban area scored higher in both scales.</p></div><div><h3>Conclusion</h3><p>This study indicates that QOL of breast cancer patients is closely linked to clinical and sociodemographic factors. Providing financial and psychological support to patients diagnosed with breast cancer may further enhance their QOL.</p></div>","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"2 ","pages":"Article 100004"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950212824000046/pdfft?md5=6f91e0b3f8c0e4d05ca4f84c4e462d82&pid=1-s2.0-S2950212824000046-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141708386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ours","authors":"","doi":"10.1016/S2950-2128(24)00017-4","DOIUrl":"10.1016/S2950-2128(24)00017-4","url":null,"abstract":"","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"2 ","pages":"Article 100017"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950212824000174/pdfft?md5=cb127cd8a10ee63a88a9fd9740464775&pid=1-s2.0-S2950212824000174-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142149514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast cancer characteristics in elderly women: A comprehensive cohort study of 7,965 patients","authors":"Massimo Lodi ,&nbsp;Nicolas Bousquet ,&nbsp;Pablo Valverde ,&nbsp;Marc De la Ferrière ,&nbsp;Karl Neuberger ,&nbsp;Stéphane Jankowski ,&nbsp;Marie-Pierrette Chenard ,&nbsp;Nathalie Reix ,&nbsp;Damien Heitz ,&nbsp;Catherine-Laure Tomasetto ,&nbsp;Carole Mathelin","doi":"10.1016/j.ibreh.2024.100001","DOIUrl":"10.1016/j.ibreh.2024.100001","url":null,"abstract":"<div><p>Purpose Breast cancer in older women is a major public health issue as there is an age-related excess mortality. Our aim was to study the tumor characteristics at diagnosis, treatment and outcomes in order to identify possible ways of improving breast cancer management in elderly women.</p><p>Methods We conducted a single-institution retrospective analysis on a cohort of 7,965 women with invasive breast cancer or Ductal Carcinoma in situ (DCIS) who were treated between 2001 and 2017. This cohort was constituted with a machine learning-based tool called SENOMETRY (NCT02810093) which allowed us to extract structured data from unstructured Electronic Health Records. Patients were divided in 3 groups according to the age at diagnosis: younger (&lt; 49, <em>N</em> = 2001), middle-aged (50 to 74, <em>N</em> = 4859) and elderly (≥ 75, <em>N</em> = 1105).</p><p>Results In elderly women breast cancer had more favorable predictive factors (more estrogen receptors <em>P</em> &lt; 0.001, less Human Epidermal growth-factor Receptor 2 overexpression <em>P</em> = 0.009) and prognostic factors (less Ki67 &gt; 30 %, <em>P</em> = 0.001) factors. Tumors were diagnosed at a more advanced local stage (<em>P</em> &lt; 0.001). Lymph node involvement decreased before 70 (ρ -0.033, <em>P</em> = 0.027) and increased again after this threshold (ρ +0.065, <em>P</em> = 0.021). Older women underwent heavier surgical procedures (<em>P</em> &lt; 0.001 to 0.049) and more surgical abstention (<em>P</em> &lt; 0.001) for invasive carcinomas while no difference was noted for patients with DCIS only (P ranged from 0.280 to 0.440). Older women had less chemotherapy (<em>P</em> &lt; 0.001). Elderly women had higher overall mortality and lower locoregional recurrence (<em>P</em> &lt; 0.001). Specific mortality increased with age after 75 (<em>P</em> = 0.042). No difference of relapse-free or overall survival was noted for axillary lymph node dissection compared to sentinel lymph node biopsy in elderly women, after adjustement on tumor size and lymph node involvement.</p><p>Conclusion Our findings suggest that axillary surgery de-escalation and earlier diagnosis would be and accessible way of improving breast cancer management in older women.</p></div>","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"1 ","pages":"Article 100001"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950212824000010/pdfft?md5=2f5b8fb5913db7fc4970d354b098b999&pid=1-s2.0-S2950212824000010-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139890584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-genetic indications for risk reducing mastectomies: Guidelines of the national college of French gynecologists and obstetricians (CNGOF)","authors":"Carole Mathelin ,&nbsp;Emmanuel Barranger ,&nbsp;Martine Boisserie-Lacroix ,&nbsp;Gérard Boutet ,&nbsp;Susie Brousse ,&nbsp;Nathalie Chabbert-Buffet ,&nbsp;Charles Coutant ,&nbsp;Emile Daraï ,&nbsp;Yann Delpech ,&nbsp;Martha Duraes ,&nbsp;Marc Espié ,&nbsp;Luc Fornecker ,&nbsp;François Golfier ,&nbsp;Pascale Grosclaude ,&nbsp;Anne Sophie Hamy ,&nbsp;Edith Kermarrec ,&nbsp;Vincent Lavoué ,&nbsp;Massimo Lodi ,&nbsp;Élisabeth Luporsi ,&nbsp;Christine M Maugard ,&nbsp;Xavier Fritel","doi":"10.1016/j.ibreh.2024.100003","DOIUrl":"https://doi.org/10.1016/j.ibreh.2024.100003","url":null,"abstract":"<div><h3>Objective</h3><p>To determine the value of performing a risk-reducing mastectomy (RRM) in the absence of a deleterious variant of a breast cancer susceptibility gene, in 4 clinical situations at risk of breast cancer.</p></div><div><h3>Design</h3><p>The French National College of Obstetricians and Gynecologists (CNGOF) Commission of Senology developed these recommendations. A policy of declaration and monitoring of links of interest was applied throughout the process of making the recommendations. Similarly, the development of these recommendations did not benefit from any funding from a company marketing a health product. The Commission of Senology adhered to the AGREE II (Advancing guideline development, reporting and evaluation in healthcare) criteria and followed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method to assess the quality of the evidence on which the recommendations were based. The potential drawbacks of making recommendations in the presence of poor quality or insufficient evidence were highlighted.</p></div><div><h3>Methods</h3><p>8 questions on 4 topics, focusing on histological, hereditary (except identified genetic abnormality), radiological (of unrecognized cancer), and radiation (history of Hodgkin's lymphoma) risks were considered. For each situation, it was determined whether performing RRM compared with surveillance would decrease the risk of developing breast cancer and/or increase survival.</p></div><div><h3>Results</h3><p>The Commission of Senology synthesis and application of the GRADE method resulted in 11 recommendations, 6 with a high level of evidence (GRADE 1+/-) and 5 with a low level of evidence (GRADE 2+/-).</p></div><div><h3>Conclusion</h3><p>There was significant agreement among the Commission of Senology members on recommendations to improve practices for performing or not performing RRM.</p></div>","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"1 ","pages":"Article 100003"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950212824000034/pdfft?md5=bd623db483b14e079371e70f3ab95ce3&pid=1-s2.0-S2950212824000034-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141439101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ours","authors":"","doi":"10.1016/S2950-2128(24)00008-3","DOIUrl":"10.1016/S2950-2128(24)00008-3","url":null,"abstract":"","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"1 ","pages":"Article 100008"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950212824000083/pdfft?md5=5637ba7a3dd5ea7f1368daaf7b216533&pid=1-s2.0-S2950212824000083-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141961563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Techniques and complications of non-genetic risk reducing mastectomies: Guidelines of the National College of French Gynecologists and Obstetricians (CNGOF)","authors":"C Mathelin ,&nbsp;E Barranger ,&nbsp;M Boisserie-Lacroix ,&nbsp;G Boutet ,&nbsp;S Brousse ,&nbsp;N Chabbert-Buffet ,&nbsp;C Coutant ,&nbsp;E Daraï ,&nbsp;Y Delpech ,&nbsp;M Duraes ,&nbsp;M Espié ,&nbsp;F Golfier ,&nbsp;AS Hamy ,&nbsp;E Kermarrec ,&nbsp;V Lavoué ,&nbsp;M Lodi ,&nbsp;É Luporsi ,&nbsp;C Maugard ,&nbsp;S Molière ,&nbsp;JY Seror ,&nbsp;X Fritel","doi":"10.1016/j.ibreh.2024.100002","DOIUrl":"10.1016/j.ibreh.2024.100002","url":null,"abstract":"<div><h3>Objective</h3><p>Based on an updated review of the international literature covering the different surgical techniques and complications of risk reducing mastectomies (RRM) in non-genetic context, the Commission of Senology of the College National des Gynécologues et Obstétriciens Français (CNGOF) aimed to establish guidelines on techniques to be chosen and their implementation.</p></div><div><h3>Design</h3><p>The CNGOF Commission of Senology, composed of 24 experts, developed these guidelines. A policy of declaration and monitoring of links of interest was applied throughout the process of making the recommendations. Similarly, the development of these recommendations did not benefit from any funding from a company marketing a health product. The Commission of Senology adhered to and followed the AGREE II (Advancing guideline development, reporting and evaluation in healthcare) criteria and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method to assess the quality of the evidence on which the recommendations were based. The potential drawbacks of making recommendations in the presence of poor quality or insufficient evidence were highlighted.</p></div><div><h3>Methods</h3><p>The Commission of Senology considered 6 questions in 4 thematic areas, focusing on oncologic safety, risk of complications, aesthetic satisfaction and psychological impact, and preoperative modalities.</p></div><div><h3>Results</h3><p>The application of the GRADE method resulted in 7 recommendations, 6 with a high level of evidence (GRADE 1+/-) and 1 with a low level of evidence (GRADE 2+/-).</p></div><div><h3>Conclusion</h3><p>There was significant agreement among the Commission of Senology members on recommendations for preferred surgical techniques and practical implementation.</p></div>","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"1 ","pages":"Article 100002"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950212824000022/pdfft?md5=86f0c5109f141e592d5d10a8d5c1f9bd&pid=1-s2.0-S2950212824000022-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141131858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}